A Review Of Jim Tananbaum’s Investment And Management Experience

Jim Tananbaum is credited for founding Foresite Capital. He established the firm as a healthcare-committed private equity company focusing on identifying the next healthcare leaders. The corporation enhances their profitability by offering them with capital, networks and information. Before launching Foresite Capital, Jim Tananbaum had co-established two of the leading biopharmaceutical firms. He is credited for establishing GelTex Pharmaceuticals that introduced two drugs into the market. Geltex accomplished manufactured these drugs for less than $80 million. In 1998, Geltex was purchased for a consideration of $1.6 billion. At the time, its flagship drug, Renagel (Renzela), had yearly revenues of over $200 million. More than 20 years after it was developed, Renzela is estimated to generate nearly $1 billion in annual revenues.

Jim is also the co-founder and CEO of Theravance, Inc. The company shares a respiratory franchise of GSK through a joint venture with Innoviva. It also completed a spin-off that resulted in the establishment of Theravance Biopharma, Inc. The two firms have a market capitalization of $3.2 billion. Tananbaum’s is credited for being behind the success of Prospect Venture Partners II and III where he served as the founding partner. Moreover, at the start of his profession, Jim was a partner at Sierra Ventures.

Jim Tananbaum remarks that the idea of founding Foresite Capital originated from his extensive experience in the healthcare industry where he had rendered his services for over 25 years. In this period, Jim says that he could point to multiple experiences that led him to recognize vital success factors that would be beneficial to entrepreneurs and different firms. According to his Medium.com blog, Foresite means to comprehend and harness healthcare’s future.

About Jim Tananbaum

Jim Tananbaum is the CEO of Foresite Capital Management. In his investment career, Tananbaum has offered his leadership skills to many investments, including Amira Pharmaceuticals, Jazz Pharmaceuticals, Amerigroup, and Healtheon. He built Foresite Capital with the objective of marrying diverse elements of his profession to establish a new investment platform.

He holds a B.S and B.S.E.E from the renowned Yale University. He also holds an M.D. and M.B.A from the revered Harvard Medical School and Harvard Business School respectively. In addition, Jim graduated from the Massachusetts Institute of Technology (MIT) with an M.S. For many years, Jim has been interested in combining hard sciences and computer science with healthcare. Driven by this interest, Jim has gone ahead to develop long-term and productive relationships with leading academicians.

Leave a Reply

Your email address will not be published. Required fields are marked *